Cancer Therapy: Clinical Phase I Trial of a Glypican-3–Derived Peptide Vaccine for AdvancedHepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

Purpose: The carcinoembryonic antigen glypican-3 (GPC3) is an ideal target of anticancer immunotherapy against hepatocellular carcinoma (HCC). In this nonrandomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3 peptide vaccination in patients with advanced HCC. Experimental Design: Thirty-three patients with advanced HCC underwent GPC3 peptide vaccination (intradermal injections on days 1, 15, and 29 with dose escalation). The primary endpoint was the safety of GPC3 peptide vaccination. The secondary endpoints were immune response, as measured by IFN-g ELISPOT assay, and the clinical outcomes tumor response, time to tumor progression, and overall

[1]  Y. Nishimura,et al.  Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma , 2005, BioDrugs.

[2]  F. Kikkawa,et al.  Glypican‐3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma , 2011, Cancer science.

[3]  M. Itkin,et al.  Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. , 2011, Clinical immunology.

[4]  Yukie Tanaka,et al.  HLA‐A2‐restricted glypican‐3 peptide‐specific CTL clones induced by peptide vaccine show high avidity and antigen‐specific killing activity against tumor cells , 2011, Cancer science.

[5]  Masao Honda,et al.  Comparative analysis of various tumor‐associated antigen‐specific t‐cell responses in patients with hepatocellular carcinoma , 2011, Hepatology.

[6]  S. Morita,et al.  Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  T. Kinoshitá,et al.  Postoperative serum α-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma , 2010 .

[8]  M. Manns,et al.  Immunotherapy of hepatocellular carcinoma , 2010, Expert review of gastroenterology & hepatology.

[9]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[10]  白川 博文.  Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma , 2010 .

[11]  T. Kinoshitá,et al.  Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. , 2010, Oncology reports.

[12]  M. Manns,et al.  A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma , 2010, BMC Cancer.

[13]  Y. Kondo,et al.  Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis , 2009, Hepatology.

[14]  H. Aburatani,et al.  Glypican-3 expression in clear cell adenocarcinoma of the ovary , 2009, Modern Pathology.

[15]  T. Hasebe,et al.  Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. , 2009, International journal of oncology.

[16]  D. Kerr,et al.  A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma , 2009, Hepatology.

[17]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[18]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[19]  M. Tsao,et al.  Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma , 2008, Modern Pathology.

[20]  Y. Nishimura,et al.  HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. , 2008, International journal of oncology.

[21]  Zheng Zhang,et al.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. , 2007, Gastroenterology.

[22]  S. Senju,et al.  Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma , 2006, Clinical Cancer Research.

[23]  S. Senju,et al.  Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. , 2006, Cancer research.

[24]  A. Ribas,et al.  A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[26]  Yusuke Nakamura,et al.  Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell–Mediated Tumor Rejection without Autoimmune Reactions in Mice , 2004, Clinical Cancer Research.

[27]  K. Shirouzu,et al.  Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses , 2004, Clinical Cancer Research.

[28]  D. Speiser,et al.  Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination , 2004, Cancer Immunology, Immunotherapy.

[29]  A. Ribas,et al.  T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[31]  Yusuke Nakamura,et al.  Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. , 2003, Biochemical and biophysical research communications.

[32]  D. Morton,et al.  Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Schlessinger,et al.  Glypican-3 Expression in Wilms Tumor and Hepatoblastoma , 2001, Journal of pediatric hematology/oncology.

[34]  D. Sinnett,et al.  Expression of glypican 3 (GPC3) in embryonal tumors , 2000, International journal of cancer.

[35]  Yasuo Ohashi,et al.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.

[36]  伊達 是志.  DNA typing of the HLA-A gene : population study and identification of four new alleles in Japanese , 1998 .

[37]  J. Cormier,et al.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.

[38]  P. Krausa,et al.  Genetic diversity of HLA-A2: evolutionary and functional significance. , 1996, Immunology today.